ClinConnect ClinConnect Logo
Search / Trial NCT06454695

Improving Treatment of Major Depressive Disorder by Reducing Negative Future-Oriented Mental Imagery

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jun 6, 2024

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Imagery Rescripting Prospective Negative Mental Images Depression

ClinConnect Summary

This clinical trial is studying a new way to help people with Major Depressive Disorder (MDD) by targeting negative thoughts about the future. Many patients with MDD find that traditional treatments don’t work well for them, so researchers want to see if a technique called "imagery rescripting" can help. In this study, half of the 50 participants will receive standard treatment along with 3-5 sessions of imagery rescripting, where they will learn to change distressing future images, like thoughts of suicide or loss, into more positive ones. The other half will only receive the standard treatment.

To be eligible, participants must be at least 18 years old, diagnosed with MDD, and have specific negative thoughts that cause them distress. All participants will complete some questionnaires and a brief online or phone interview at the start of the study. After finishing the study, they will receive a €25 reimbursement. This pilot study aims to find out if this new approach is acceptable and feasible for patients, which will help in planning a larger study in the future to better understand its effectiveness. There are no major risks involved in participating, making it a safe option for those who qualify.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Aged 18 years or older;
  • Meet DSM-5 criteria for major depressive disorder;
  • Presence of 1-3 negative future-oriented mental images, which cause distress;
  • Be able to understand questionnaires and study information letter;
  • In case of medication use: are stable on medication for six weeks or longer.
  • Exclusion Criteria:
  • Current or history of psychotic disorder;
  • Current or history of bipolar disorder;
  • Severe cognitive impairment (e.g., mental retardation) as evidenced by educational records, parental report and/or clinical impression;
  • Current EMDR or imagery rescripting therapy;
  • Other circumstances that might affect participation (e.g., severe medical disorder, relocation).

About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)

The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.

Locations

Amsterdam, Noord Holland, Netherlands

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported